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NeuroprotectionObjectives: This study was done to estimate the potential neuroprotective role of potassium channel
openers in cerebral ischemia–reperfusion (IR) injury in streptozotocin (STZ) induced type-I diabetic rats
(T1DR).
Methods: Potassium channel openers – cromakalim, cinnarizine and nicorandil; potassium channel
blocker –glibenclamide, insulin (as an antidiabetic standard), telmisartan (as an anti-hypertensive stan-
dard agent) and vitamin E (as an antioxidant and antiapoptotic standard agent) were given for 3 days in
streptozotocin (45 mg/kg i.v.) induced type I diabetic rats along with middle cerebral artery occlusion.
After 24 h of surgery, plasma glucose, neurobehavioral score, cerebral infarct volume, blood pressure
and caspase-3 levels were measured to evaluate the mechanism of potassium channel openers (KCOs)
for neuroprotection.
Results: Following STZ administration and ischemia–reperfusion, blood sugar, neurobehavioral score,
cerebral infarct volume and caspase-3 levels were significantly high in diabetic-IR groups. Treatment
with cromakalim, cinnarizine, nicorandil, insulin and vitamin E significantly reduce neurobehavioral
score while nicorandil and vitamin E significantly reduced cerebral infarct volume. Caspase-3 levels were
significantly reduced by cromakalim and nicorandil treated animals. Except insulin and glibenclamide,
none of the agents significantly reduce plasma glucose levels.
Conclusion: Treatment of ischemic stroke with potassium channel openers in T1DR is neuroprotective.
Inhibition of apoptosis may contribute to their neuroprotective effects after stroke in T1DR.
 2016 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cerebral ischemic stroke is caused due to obstruction of blood
supplied to the brain. It is classified either as ischemic stroke (IS)
or hemorrhagic stroke. There are around 83% cases of strokes with
IS while the remaining have hemorrhagic brain stroke which
results in leakage of blood into the brain. Important etiological fac-
tors for pathogenesis include hypercholesterolemia, hypertension
and hyperglycemia. It is reported that diabetes mellitus (DM)
increases the risk of brain stroke 2 to 3 times more. DM increases
the risk of macrovascular and microvascular complications [1,2].Current treatments options for brain stroke include the use of anti-
platelet agents and tissue plasminogen activators (tPA) for their
thrombolytic effects. Anti-oxidants such as vitamin C, E and
growth factors are found to be neuroprotective in IS. Furthermore,
anti-hypertensives, anti-hyperlipidemics as well as oral hypo-
glycemic agents are beneficial for prevention of IS [3].
However, tPA treatment of stroke after 3 h in patients with DM
increases the risk of death and intracerebral hemorrhage [4,5].
Even, reports have found that tPA treatment within 2 h after stroke
in type-I diabetic rats significantly increases brain hemorrhage,
and increases neurobehavioral score after stroke [6,7]. Thus, there
is a need to identify new treatment agents with neuroprotective
action in IS and its related disorders like diabetes.
K+ ion channels of CNS (central nervous system) play an impor-
tant role for providing neuroprotection in animal models of
ischemic brain stroke [8]. ATP sensitive potassium channel openers
such as nicorandil and cromakalim showed free radical scavenging
effect and anti-apoptotic effect in streptozotocin-induced diabeticjury in
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tive action IR injury through anti-apoptotic, anti-oxidant and
anti-inflammatory actions in various experimental animal models
[12]. Thus they are newer therapeutic treatment targets for neuro-
protection in ischemic brain stroke. However, their mechanism of
neuroprotection in stroke and its related disorders like DM remains
unknown. Present acute type of study assumed that potassium
channel openers might treat IR injury in STZ induced type-I dia-
betes mellitus by inhibiting apoptosis pathways. Animal model of
IR was induced by cerebral artery occlusion in STZ induced type -
1 diabetes mellitus (T1DM). The neuroprotective actions of potas-
sium channel openers cromakalim, nicorandil and cinnarizine were
determined to find out the mechanism of action in diabetic rats.2. Materials and method
2.1. Drugs and chemicals
All the drugs and chemicals for study were of laboratory grade.
Except vitamin E, all other drug solutions were freshly prepared in
distilled water and given intraperitoneally (i.p.) in appropriate
doses as written in the experimental design section. STZ solution
was dissolved in phosphate buffer and given 45 mg/kg intra-
venously (i.v.). Vitamin E suspension was prepared by dissolving
it in 4% tween 80 and given orally. Here, cromakalim, cinnarizine
and nicorandil were taken as potassium channel opener agents.
Glibenclamide was taken as potassium channel blocker. Insulin,
telmisartan and vitamin E were taken as antidiabetic, anti-
hypertensive and antioxidant-antiapoptotic standard agents
respectively.2.2. Animals
Adult male Wistar Albino rats weighing between 180 and 210 g
were procured from the Animal House of Parul Institute of Phar-
macy, Vadodara. The animal experimental protocols, including all
use, care, and operative procedures, were approved by the Institu-
tional Animal Ethics Committee (IAEC). Every effort was made to
minimize the number of animals used and their suffering. Animals
were maintained at 18 ± 2 C in polypropylene cages with food and
water ad libitum. Animals were divided into sixteen groups.2.3. Experimental design
Group 1 (normal control, n = 6) animals were administered with
tween 80 (4%). Group 2 (Diabetic control, n = 6) animals were
administered with STZ (45 mg/kg i.v) on 1st day. On day 3, diabetic
glucosuria was confirmed using Diachex urine strip. Group 3 (Dia-
betic Sham surgery operated, n = 6) animals were given with tween
80 (4%) for 3 days along with STZ on 1st day. Sham surgery was
done on 2nd day. Group 4 (IR control, n = 12) animals received
tween 80 (4%) for 3 days. IR was done on 2nd day from initiation
of experiment. Group 5 (n = 12), 6 (n = 12), 7(n = 12) and 8
(n = 12) were induced with IR and treated with cromakalim
(10 mg/kg i.p.) [13], cinnarizine (5 mg/kg ip) [14], nicorandil
(5 mg/kg ip) [15] and vitamin E (150 mg/kg orally) [16] respec-
tively for 3 days. Group 9 (Diabetic-IR control, n = 12) animals were
administered with tween 80 (4%) for 3 days after STZ (45 mg/kg i.
v.) induced diabetes. Cerebral IR was done on 2nd day. Group 10
animals (n = 12) were administered with cromakalim (10 mg/kg i.
p. for 3 days) along with STZ (45 mg/kg i.v. on 1st day) along with
IR injury on 2nd day. Similarly group 11 (n = 12), 12 (n = 12), 13
(n = 12), 14 (n = 12), 15 (n = 12), and 16 (n = 12), were treated with
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2.4. Induction of cerebral ischemia–reperfusion injury
Cerebral IR was induced as per transient middle cerebral artery
occlusion (tMCAO) method of Wang et al. [13]. Rats were anes-
thetized with an i.p. injection of 100 mg/kg ketamine. A 2–3 cm
incision was made in the middle of the neck line, separating the
left carotid artery, the superior thyroid artery, and the occipital
artery, as well as the internal and external carotid communicating
arteries. The occipital artery branches of external carotid artery
(ECA) were isolated and tied with a cotton thread. Cotton thread
was tied loosely around the ECA stump near the bifurcation. Then
internal carotid artery (ICA) and common carotid artery (CCA) were
temporarily occluded by a fine vessel clip. Through a small incision
to the ECA stump, blunt Poly-L-lysine coated 4-0 monofilament
was inserted from the left external carotid artery into the left inter-
nal carotid artery to a depth of 18.0 mm, vessel clip from ICA
removed. After a variable length of suture had been inserted into
the ECA stump, resistance was felt and slight curving of suture
was observed, indicating that the suture had passed the middle
cerebral artery (MCA) origin and reached to proximal segment of
anterior cerebral artery (ACA-it has small diameter). Hence the
suture had blocked all sources of blood from ICA, ACA and posterior
cerebral artery. Finally the vessel clip from CCA was removed to
restore the blood flow. The midline incision was closed, leaving
the suture protruding so it could be withdrawn to allow reperfu-
sion. The thread was maintained for 2 h and subsequently removed
to restore blood flow to the common carotid and internal carotid
arteries. Here 18 mm of suture was pulled back until resistance
was felt, indicating that the tip cleared the ACA-ICA lumen and
was in the ECA stump, then trimmed. The animals were transferred
to a fresh cage with free access to food and water.
2.5. Tissue homogenate preparation
Brain samples were washed with isotonic saline and homoge-
nized using ice-cold 10% w/v 0.1 M phosphate buffer of pH 7.4.
Supernatant was obtained by centrifuging the homogenate at
12000 rpm (20 min). This supernatant was used to estimate
caspase-3 [20].
2.6. Tissue total protein level
It was estimated as per the method of Lowry et al. [21] using
bovine serum albumin, alkaline copper reagent Solution A (2%
sodium carbonate in 0.1 N NaOH solution in distilled water), solu-
tion B (0.5% copper sulfate in 1.0% sodium potassium tartarate) and
Folin’s phenol reagent.
2.7. Plasma glucose levels
Glucometer (One Touch Ultra 2, Lifescan Inc, USA) was used to
estimate glucose levels.
2.8. Neurobehavioral score
Neurobehavioral score was obtained for the group after 24 h of
IR injury [22]. This score was monitored for group 4 to 16. Score 0:
no behavioral deficit; score 1: forelimb flexion and positive tail
suspension test; Score 2: Reduced hold of the forelimb when tail
pulled; Score 3: Spontaneous circling or contralateral circling
movement when tail pulled; Score 4: Spontaneous circling; Score
5: Death.of potassium channel openers on cerebral ischemia–reperfusion injury in
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Coronal brain sections (2 mm thickness) were made from the
forebrain region and immersed with 2% 2, 3, 5 triphenyltetra-
zolium chloride solution at 37 C for 30 min. These slices were kept
into 10% paraformaldehyde solution for fixing purpose. Total
infarct volume was calculated by summing up the unstained
infarct areas in each section and multiplying it by slice thickness
of 2 mm [23].2.10. Caspase-3 activity assay
Caspase 3 levels of brain tissue homogenate were measured by
the use of an ELISA-based assay kit, produced by Shanghai Crystal
day Biotech Co., Ltd., China.Fig. 2. Effect of cromakalim, cinnarizine, nicorandil and vitamin E on neurological
score. Data presented as mean ± SEM, asteriks (¥) indicate significant difference
from the IR control rats, (d) indicate significant difference from diabetic IR control2.11. Blood pressure
It was measured by the invasive method before sacrificing the
animals [24].rats at p < 0.05.2.12. Statistical methods
All the data were expressed as mean ± SEM and evaluated using
a one-way ANOVA and Tukey’s post hoc test to identify two group
differences at p < 0.05.3. Results
3.1. Plasma glucose levels
STZ (45 mg/kg i.v.) significantly increase plasma glucose levels
in diabetic animals (565.33 ± 9.61), diabetic sham operated
(530.16 ± 25.83) and diabetic IR animals (479.16 ± 31.56) animals
in comparison with normal animals (138.5 ± 13.3). Treatment with
glibenclamide and insulin significantly decreases blood glucose
levels to 147 ± 13.61, 137.66 ± 16.27 respectively in comparison
with diabetic IR animals (Fig. 1).Fig. 1. Effect of cromakalim, cinnarizine, nicorandil and vitamin E on plasma
glucose levels. Data presented as mean ± SEM, asteriks (⁄) indicate significant
difference from the normal control and (d) indicate significant difference from
diabetic IR control rats at p < 0.05.
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Treatment of cromakalim, cinnarizine, nicorandil and vitamin E
significantly reduced brain neurobehavioral score (2.62 ± 0.39,
2.96 ± 0.25, 2.88 ± 0.21, 2.86 ± 0.21 respectively) when compared
with IR animals (3.89 ± 0.28). Treatment with cromakalim, cinnar-
izine, nicorandil, insulin and vitamin E significantly reduced neu-
robehavioral score to 3.14 ± 0.14, 3.22 ± 0.15, 3.18 ± 0.05,
3.22 ± 0.07 and 3.56 ± 0.208 when compared with diabetic IR
(4.26 ± 0.25) animals (Fig. 2).3.3. Cerebral infarct volume
Treatment of cromakalim, cinnarizine, nicorandil and vitamin E
significantly reduced cerebral infarct volume (48.66 ± 4.58,
54.55 ± 4.49, 41.83 ± 3.02, 47.41 ± 3.45 respectively) when com-
pared with IR control animals (81.45 ± 2.40). Treatment with nico-
randil and vitamin E significantly reduced cerebral infarct volume
to 43.02 ± 2.49, 45 ± 0.95 when compared with diabetic IR
(61.80 ± 3.38) animals (Fig. 3).3.4. Caspase-3 levels
Caspase-3 levels were significantly high in diabetic animals
(226.57 ± 65.29), diabetic sham operated (106.94 ± 31.90) and dia-
betic IR (167.67 ± 49.15) animals when compared with normal ani-
mals (89.67 ± 26.35). Treatment of cromakalim, cinnarizine,
nicorandil and vitamin E significantly reduced brain caspase-3
levels 110.83 ± 32.60 when compared with IR animals
(180.84 ± 52.44). Treatment with cromakalim and nicorandil sig-
nificantly reduced caspase-3 levels to 92.64 ± 26.66 and
92.99 ± 27.74 when compared with diabetic IR (167.67 ± 49.15)
animals (Fig. 4).3.5. Blood pressure
For the results of blood pressure, there was no significance
among various groups (Fig. 5).of potassium channel openers on cerebral ischemia–reperfusion injury in
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Fig. 3. Effect of cromakalim, cinnarizine, nicorandil and vitamin E on cerebral
infarct volume. Data presented as mean ± SEM, asteriks (¥) indicate significant
difference from the IR control rats, (d) indicate significant difference from diabetic
IR control rats at p < 0.05.
Fig. 4. Effect of cromakalim, cinnarizine, nicorandil and vitamin E on caspase-3
levels. Data presented as mean ± SEM, asteriks (⁄) indicate significant difference
from the normal control rats, (¥) indicate significant difference from diabetic IR
control rats and (d) indicate significant difference from diabetic IR control rats at
p < 0.05.
Fig. 5. Effect of cromakalim, cinnarizine, nicorandil and vitamin E on mean blood
pressure. Data presented as mean ± SEM and indicate non-significant difference
among various groups.
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In the present study we have investigated the effect of potas-
sium channel openers against IR model of brain injury along with
STZ induced diabetes. Resulted symptoms resemble that observed
in clinical status. We demonstrated that KCOs improve functional
outcome by significantly reducing cerebral infarct volume and cas-
pase enzyme levels. Inhibition of apoptosis may contribute to KCOS
induced neuroprotective effect after ischemic stroke of T1DR.
Numerous studies reported high prevalence of stroke associated
with diabetes [24]. Experimental studies on rats were done to rule
out correlation between ischemic brain stroke and diabetes. Evi-
dence showed that high blood sugar by STZ decreases blood flow
to the brain by 37% and it is associated with raised cerebral infract
diameter in the penumbral brain region. Oxidative stress, apopto-Please cite this article in press as: A.B. Pithadia et al., Neuroprotective effects
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nisms for neuronal injury with diabetes [25,26]. STZ diabetic
animals with stroke have significantly raised apoptosis when com-
pared to non-diabetic stroke animals [27]. In present study, we had
used three KCOs namely cromakalim, nicorandil and cinnarizine.
All three agents produced significant neuroprotection in terms of
neurobehavioral score in comparison with IR animals and diabetic
IR control animals. These effects are consistent with vitamin E and
insulin. Further, all three KCOs and vitamin E showed a significant
reduction in cerebral infarct volume when compared with IR con-
trol animals. However, only nicorandil and vitamin E significantly
reduce infarct volume when compared with diabetic IR animals.
Apoptosis is a programed cell death that occurs in chronic neu-
rodegenerative disorders such as stroke, Alzheimer’s and Parkin-
son’s diseases. It comprises two pathways intrinsic and extrinsic.
Both pathways involve events with a series of caspase enzymes
[28,29]. Apoptosis of neuronal cells is an important factor to neu-
rological deficiencies with diabetes. Ischemic stroke exaggerates
these neuronal deficiencies. Caspase-3 is one of the most abundant
caspases among other members in the rat brain [30]. Recent ani-
mal experimental evidence indicates involvement of apoptosis in
neurodegeneration after ischemic brain injury. Intracerebroven-
tricular injection of caspases peptide inhibitor reduced caspase
end products, cerebral IL-1b levels, reduced tissue damage and sig-
nificantly improved behavioral deficits in ischemic mouse brain.
Furthermore the same pathways and mechanisms are involved in
pancreatic b cell destructions that lead to diabetes mellitus and
high blood sugar level is associated with pathogenesis of stroke
[31,32]. Intracerebral injection of a caspase-3 inhibitor protected
against a-amino-3-hydroxy-5-methyl-4-isoxazole propionate
mediated excitotoxicity and brain damage. Caspase inhibitors pro-
vide neuroprotection to ischemic animals [33]. After hypoxia and
ischemia neurons apoptosis mediated via caspase-3 [34].
Studies have shown that caspase-3 mediated apoptosis path-
ways are activated during acute cerebral ischemia and play a cru-
cial role in ischemic nerve injury at cellular and molecular levels
[35,36]. Influx of K+ current and hyperpolarization of cell prevent
apoptosis and blocking of K+ ion channels was suggested to induce
apoptosis [37]. Data of our study revealed that caspase-3 levels
were significantly high in diabetic IR animals. Cromakalim and
nicorandil significantly reduced its levels. Therefore, a reductionof potassium channel openers on cerebral ischemia–reperfusion injury in
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hyperpolarization of cells, attenuate apoptosis and reducing infarct
volume after stroke in diabetic animals. These data are comparable
with standard ant-oxidant and anti-apoptotic vitamin E treated
animals. Vitamin E produced anti-apoptotic and neuroprotective
effects by inhibiting caspase-3 enzyme against hypoxia and reper-
fusion injury to rats [38].
It is known that potassium channel openers produce vasodila-
tion and reduce blood pressure [39]. High blood pressure is one
of the causes of hemorrhagic brain stroke [1]. Hence to rule out
involvement of such a mechanism of action by KCOs, we had trea-
ted animals with antihypertensive telmisartan and more over the
blood pressure of each group of animal was noted down. However,
telmisartan treated animals didn’t show any neuroprotective
action and blood pressure of each group of animals remains unaf-
fected. Secondly we had treated animals with two anti-diabetic
drugs namely ATP sensitive potassium channel blocker gliben-
clamide and insulin. Except lowering of blood sugar level, gliben-
clamide didn’t show any significant neuroprotective activity.
Insulin treated animals showed a significant lowering of neurobe-
havioral score in diabetic IR animals. This insulin (antidiabetic
standard) mediated action is supported by previous findings that
insulin showed neuroprotective action by reducing cerebral infarct
volume and apoptosis in diabetic rats with MCAO (middle cerebral
artery occlusion) [40]. Thus neuroprotective action by KCOs is
independent of blood pressure and glucose lowering activity. It
may be due to opening of potassium ion channels and prevention
of apoptosis through inhibition of caspase enzyme.
In this study, we for the first time demonstrated cromakalim
and nicorandil treatment promotes neuroprotection after stroke
in type-I diabetic rats. However, mechanisms by which KCOs pro-
duce neuroprotective effects need further study and investigation.5. Conclusions
We found that cromakalim and nicorandil treatment promotes
functional outcome after ischemic stroke in type-I diabetic rats.
Anti-apoptotic effects may contribute to neuroprotective effects
by KCOs after ischemic stroke in type-I diabetic rats.Conflict of interest
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